文献速递胸部肿瘤支持与姑息治疗

糖皮质激素对晚期非小细胞肺癌免疫检查点抑制剂治疗结局的影响

Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
PubMed 文献 · Eur J Cancer · 2021-01-05

该研究回顾性分析了瑞典卡罗林斯卡大学医院196例接受免疫检查点抑制剂(ICI)治疗的晚期非小细胞肺癌(NSCLC)患者的临床数据,以评估使用糖皮质激素的时间以及原因对生存结局的影响。结果显示,46.3%的患者接受了糖皮质激素;因免疫相关不良事件(irAE)使用激素不影响总生存(OS)(p=0.38),而仅因姑息癌症相关症状使用激素是OS缩短的独立预测因素(HR=2.7;95%CI,1.5-4.9);激素使用的时间线不影响OS(p=0.456)。

要点

  • 因irAE使用激素不影响ICI疗效,OS与未用激素组无差异(p=0.38)。
  • 仅因姑息癌症相关症状使用激素与更短OS独立相关(HR=2.7;95%CI,1.5-4.9)。
  • 激素使用时间线(ICI启动前2周至后2天内 vs 更晚)不影响OS(p=0.456)。

核心结论

  • 因irAE使用激素似乎不削弱ICI疗效,而因姑息恶性肿瘤相关症状使用高剂量激素可能反映该患者群体预后不良。

研究设计与样本

  • 回顾性收集卡罗林斯卡大学医院非致癌驱动基因突变的晚期NSCLC接受ICI治疗患者的临床数据,共分析196例。
  • 激素使用定义为泼尼松龙等效剂量>10 mg且持续≥10天。
  • 按激素使用原因分三组:支持治疗非癌症姑息、癌症相关症状姑息、irAE管理;按时间线分ICI启动前2周至后2天内使用与治疗后期使用两组。

主要发现

  • 196例患者中46.3%接受了糖皮质激素。
  • 因irAE使用激素与未用激素组相比,OS无显著差异(p=0.38)。
  • 仅因姑息癌症相关症状使用激素是OS缩短的独立预测因素(HR=2.7;95%CI,1.5-4.9)。
  • 激素使用时间线不影响OS(p=0.456)。

临床怎么用

  • 对因irAE需要使用激素的晚期NSCLC患者,不必因担心削弱ICI疗效而回避激素。
  • 因癌症相关症状需要高剂量激素姑息的患者,提示预后可能较差,应加强整体评估与支持治疗。

局限性

  • 为单中心回顾性研究,样本量196例,结论需前瞻性研究验证。
  • 激素使用定义及分组依赖病历记录,可能存在混杂与信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We analysed patients with advanced non-small cell lung cancer (NSCLC) who were treated with immune-checkpoint inhibitors (ICIs) to address the effect of the timeline and reason for corticosteroid administration on survival outcomes. METHODS: We retrospectively collected clinical data of non-oncogenic driven, advanced NSCLC patients treated with ICIs at Karolinska University Hospital, including the timeline and reason for steroid administration. Steroid administration was defined as > 10 mg prednisolone equivalent for ≥10 days. We subcategorized patients based on the aetiology of steroid administration into three subgroups: a) steroids for supportive reasons but not for cancer palliation; b) steroids for the palliation of cancer-related symptoms; c) steroids for the management of immune-related adverse events (irAEs). Furthermore, to analyse the timeline, patients were categorised into two groups; those who received corticosteroids within 2 weeks before until 2 days after ICI initiation and those who received steroids later during their treatment course. RESULTS: Analysed data from 196 patients showed 46.3% of patients received corticosteroids. Steroid administration due to irAEs did not affect overall survival (OS) (p = 0.38) compared with the steroid naïve group. Only steroid administration for the palliation of cancer-related symptoms was an independent predictor for shorter OS (HR = 2.7; 95% CI, 1.5-4.9). The timeline of steroid administration did not affect OS (p = 0.456) in our cohort. CONCLUSIONS: Steroids due to irAEs do not appear to hamper ICI efficacy. However, the administration of high-dose steroids to palliate malignancy-associated symptoms might reflect the dismal prognosis of this patient group.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Skribek M, Rounis K, Afshar S, et al. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer. 2021. PMID: 33419647. doi:10.1016/j.ejca.2020.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。